Why Is Bluejay Diagnostics Stock Soaring Tuesday?

Bluejay Diagnostics Inc. (NASDAQ:BJDX), a medical diagnostics company focused on near-patient testing for critical care, announced a strategic partnership with Argonaut Manufacturing Services to support the advancement of Bluejay’s Symphony platform.

Shares of Bluejay surged more than 200% in premarket trading Tuesday following the announcement.

Bluejay Focuses On Rapid Sepsis Testing Technology

The medical diagnostics company is using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression.

Bluejay does not yet have regulatory clearance for the Symphony System and will need to receive authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the U.S.

The company’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate and reliable results in approximately 20 minutes from sample to result, helping medical professionals make earlier triage and treatment decisions.

Partnership Aims To Expand U.S. Manufacturing And Commercial Infrastructure

The partnership is designed to support Bluejay’s broader efforts to establish scalable U.S.-based manufacturing capabilities aligned with its ongoing clinical development programs and future commercialization objectives.

In addition, the partnership is intended to strengthen Bluejay’s future commercial infrastructure by supporting broader product distribution across the U.S., enhancing supply chain resilience, and reducing potential risks associated with international sourcing and import tariffs.

The collaboration is also intended to mitigate risks associated with Bluejay’s current reliance on overseas manufacturing by establishing domestic manufacturing capabilities that can provide greater operational control, business continuity, and supply chain security.

By leveraging U.S.-based manufacturing and distribution capabilities, Bluejay aims to improve operational flexibility, support future market demand, and further enhance its ability to commercialize innovative near-patient diagnostic solutions for critical care settings.

BJDX Stock Price Activity: Bluejay Diagnostics shares were up 212.90% at $6.79 during premarket trading on Tuesday, according to Benzinga Pro.

Photo by PeopleImages.com – Yuri A via Shutterstock